Key result
Ticagrelor augmented maximal coronary blood flow velocity area under the curve to a greater extent than prasugrel during adenosine infusion (mean difference 7.16; 95% CI 2.61-11.7; P=0.003).
Why the study?
Does ticagrelor improve coronary blood flow velocity to a greater extent than prasugrel in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention?
Population
56 patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention
Comparison
Ticagrelor 90 mg BID for a 15-day treatment period vs Prasugrel 10 mg OD for a 15-day treatment period
Design
RCT, randomized, single-blind
Follow-up
15 days per treatment period
Authors
Loading...
Ticagrelor may augment adenosine-induced coronary flow more than prasugrel; hypothesis-generating for clinical outcomes in ACS.
RCT (n=56)
Single-blind
randomized
No
Does ticagrelor improve coronary blood flow velocity to a greater extent than prasugrel in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention?
Mean Difference: 7.16 (95% CI 2.61–11.7)
p-value: p=0.003
Ticagrelor augments coronary blood flow velocity to a greater extent than prasugrel during adenosine infusion in NSTE-ACS patients, suggesting a potential pleiotropic mechanism.
Alexopoulos et al. (2013) conducted an RCT in Non-ST-elevation acute coronary syndrome (n=56). Ticagrelor vs. Prasugrel 10 mg OD was evaluated on Maximal coronary blood flow velocity area under the curve (MD 7.16, 95% CI 2.61-11.7, p=0.003). Ticagrelor augmented maximal coronary blood flow velocity area under the curve to a greater extent than prasugrel during adenosine infusion (mean difference 7.16; 95% CI 2.61-11.7; P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: